Should antibiotics be given for Buruli ulcer?

The Lancet

Volumn 375, Issue 9715, 2010, Pages 618-619

  Johnson, Paul DR ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SKIN DISEASE; BURULI ULCER; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; DISEASE TRANSMISSION; DRUG INDICATION; ENDEMIC DISEASE; ERADICATION THERAPY; EXCISION; GHANA; HUMAN; MAJOR CLINICAL STUDY; MOBILE PHONE; MYCOBACTERIUM ULCERANS; PRACTICE GUIDELINE; PRIORITY JOURNAL; TECHNOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME; ULCER HEALING; VESTIBULAR DISORDER; WORLD HEALTH ORGANIZATION;

EID: 76749137061     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60169-9     Document Type: Note

References (12)

1. Nienhuis W.A., Stienstra Y., Thompson W.A., et al. aAntimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet (2010) 10.1016/S0140-6736(09)61962-0 published online Feb 4.
2. Johnson P.D., Stinear T., Small P.L., et al. Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2 (2005) e108
3. van der Werf T.S., van der Graaf W.T., Tappero J.W., and Asiedu K. Mycobacterium ulcerans infection. Lancet 354 (1999) 1013-1018
4. Revill W.D., Morrow R.H., Pike M.C., and Ateng J. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 2 (1973) 873-877
5. Fehr H., Egger M., and Senn I. Cotrimoxazol in the treatment of Mycobacterium ulcerans infection (Buruli ulcer) in west Africa. Trop Doct 24 (1994) 61-63
6. Espey D.K., Djomand G., Diomande I., et al. A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis 6 (2002) 60-65
7. Jenkin G.A., Smith M., Fairley M., and Johnson P.D. Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust 176 (2002) 180-181
8. Johnson P.D., Hayman J.A., Quek T.Y., et al. Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust 186 (2007) 64-68
9. O'Brien D.P., Hughes A.J., Cheng A.C., et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 186 (2007) 58-61
10. Etuaful S., Carbonnelle B., Grosset J., et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49 (2005) 3182-3186
11. Chauty A., Ardant M.F., Adeye A., et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51 (2007) 4029-4035
12. O'Brien D.P., Robson M.E., Callan P.P., and McDonald A.H. "Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 191 (2009) 564-566